You are here

CP-751,871 Treatment For Patients With Multiple Myeloma

Last updated on May 9, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Phoenix, Arizona, 85054 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Multiple Myeloma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Previously treated multiple myeloma with a quantifiable serum (M spike ≥ 1 g/dL)
and/or urine (≥ 200 mg/24-hr) paraprotein

- Adequate bone marrow, renal, liver and cardiac function

- Eastern Cooperative Oncology Group [ECOG] performance status less than or equal to 2

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Prior allogeneic stem cell transplant (alloSCT)

- Myelosuppressive chemotherapy or immunotherapy within 3 weeks prior to treatment with
CP-751,871

- Prior organ allograft

- Concurrent use of insulin, oral hypoglycemic medication, growth hormone (GH), or
growth hormone inhibitors

- Female patients who are pregnant or lactating

NCT01536145
Pfizer
Completed
CP-751,871 Treatment For Patients With Multiple Myeloma

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Neoplasms, Thrombocytopenia, Multiple Myeloma, Malignant Lymphoma
NCT00037791
All Genders
18+
Years
Multiple Sites
Multiple Myeloma
NCT03269136
All Genders
18+
Years
Multiple Sites
Secondary Progressive Multiple Sclerosis
NCT00146159
All Genders
18+
Years
Multiple Sites
Relapsing-Remitting Multiple Sclerosis
NCT00228397
All Genders
CP-751,871 Treatment For Patients With Multiple Myeloma
An Open Label Phase I Study Of CP-751,871 In Patients With Multiple Myeloma
This study represents the first-in-human study for CP-751,871. The study aimed to define the safety, tolerability, and maximum tolerated dose of CP-751,871 in patients with multiple myeloma through a dose escalation design.
Not Provided
Interventional
Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Multiple Myeloma
Drug: CP-751,871
CP-751,871 was given at doses ranging from 0.025 mg/kg up to 20 mg/kg IV every 4 weeks until disease progression or lack of tolerability
Experimental: Single agent CP-751,871
dose escalation design
Intervention: Drug: CP-751,871
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
47
June 2008
June 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Previously treated multiple myeloma with a quantifiable serum (M spike ? 1 g/dL) and/or urine (? 200 mg/24-hr) paraprotein
  • Adequate bone marrow, renal, liver and cardiac function
  • Eastern Cooperative Oncology Group [ECOG] performance status less than or equal to 2

Exclusion Criteria:

  • Prior allogeneic stem cell transplant (alloSCT)
  • Myelosuppressive chemotherapy or immunotherapy within 3 weeks prior to treatment with CP-751,871
  • Prior organ allograft
  • Concurrent use of insulin, oral hypoglycemic medication, growth hormone (GH), or growth hormone inhibitors
  • Female patients who are pregnant or lactating
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01536145
A4021001
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
March 2013

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now